Becklund Irene sold $371K of HIMS

Becklund Irene (PAO) sold 12,063 shares of Hims & Hers Health, Inc. (HIMS) at an average of $30.72 ($30.25–$31.50, $0.37M total) across 2 trades over 2026-06-16 to 2026-06-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Becklund Irene
Published Jun 17, 2026, 10:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 17, 2026, 10:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$HIMS
Neutral
high confidence
Mentioned
$HIMS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HIMSNeutralLow
01

Why it matters

The newest disclosed fact is the specific insider sale size, dates, and weighted-average price under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note a modest sentiment headwind from insider selling, but the 10b5-1 structure limits fundamental interpretation.

03

What to watch

Insider sales can cluster around tax/vesting schedules; without context on total insider activity or subsequent buys, the signal is weak.

Relevance 3/10Novelty 6/10Timing: Filed 2026-06-17; trades occurred 2026-06-16 to 2026-06-17.

Background

The article is an SEC Form 4 insider transaction disclosure for Hims & Hers Health, Inc.

Company-level read

Ticker impact

$HIMSNeutralHigh confidence
Context

Hims & Hers Health insider Becklund Irene sold $370.5K of HIMS shares via a Rule 10b5-1 plan (2 trades, $30.25–$31.50).

Expected impact

Likely small/short-lived negative bias; no clear directional catalyst beyond sentiment.

Evidence & confidence

The filing is a Form 4 insider sale with explicit 10b5-1 pre-arrangement, which typically reduces interpretive weight versus discretionary selling.

Market effects

Minimal read-through to the digital health/telehealth sector; this is company-specific insider activity without operational updates.

None indicated.

None indicated.

Counterpoint

10b5-1 sales can be purely liquidity-driven; the sale may not reflect bearish expectations and could be offset by other insider buys or institutional flows not shown here.

Key entities

  • Hims & Hers Health, Inc.

    Subject of the Form 4 insider sale by officer Becklund Irene.

  • Becklund Irene

    Officer who executed two open-market sales totaling 12,063 shares under a Rule 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$HIMSHighAI 8/10

Hims & Hers Jumped 6% as RFK Jr.’s HHS Uses “Enforcement Discretion” to Open Peptide Compounding

Hims & Hers Health (HIMS) shares rose 6% after HHS announced enforcement discretion for six peptides, potentially benefiting Hims' peptide facility. The company awaits final FDA rules for a full launch. Hims' gross margin fell to 63.8% in Q2, with Q3 results on Nov. 9. Analysts estimate the peptide market at $2.2B-$3.3B, and Hims' revenue at $4.49B by 2028.

$HIMSMed

Hims Seeks Dismissal of FTC Suit Over User Data, Subscriptions

Hims & Hers Health Inc. asked a California judge to dismiss an FTC lawsuit alleging deceptive practices, improper data sharing, and difficult subscription cancellations. The company claims its privacy policy is clear and the FTC misapplied federal law. The FTC argues Hims violated a 2010 law requiring clear disclosure of subscription terms. Hims has 2.6 million subscribers. A hearing is scheduled for January 7.